Prakt. lékáren. 2020; 16(4): 208-214

Drug interactions in urology - what to watch out for

Josef Suchopár, Michal Prokeš, Štěpán Suchopár
DrugAgency, a. s., Praha

Drug interactions are a problem in all medical disciplines including urology. A number of typically urological drugs such as drugs for the treatment of overactive bladder, benign prostatic hyperplasia or erectile dysfunction are substrates of CYP3A4 and the P-glycoprotein transport system. Combination of these drugs with inhibitors or inducers of CYP3A4 or P-glycoprotein can either lead to adverse events or reduce the effect to failure. In addition, manufacturers often recommend changes in drug dosage when combined with CYP3A4 inhibitors and it may be difficult for physicians to navigate such recommendations.

Keywords: drug interactions, alpha-blockers, 5-alpha reductase inhibitors, antimuscarinics, PDE5 inhibitors, CYP3A4, CYP2D6, P-glycoprotein, OAB, ED, LUTS.

Published: January 5, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Suchopár J, Prokeš M, Suchopár Š. Drug interactions in urology - what to watch out for. Praktické lékárenství. 2020;16(4):208-214.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Wakuda H, et al. Effects of Anticholinergic Drugs Used for the Therapy of Overactive Bladder on P-Glycoprotein Activity. Biol Pharm Bull 2019; 42: 1996-2001. Go to original source... Go to PubMed...
    2. Paśko P, et al. A short review of drug-food interactions of medicines treating overactive bladder syndrome. Int J Clin Pharm 2016; 38: 1350-1356. Go to original source... Go to PubMed...
    3. Kerbusch T, et al. Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability. Br J Clin Pharmacol 2003; 56: 639-652. Go to original source... Go to PubMed...
    4. Krauwinkel W, et al. The effect of mirabegron, a potent and selective β3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol. Eur J Drug Metab Pharmacokinet 2014; 39: 43-52. Go to original source... Go to PubMed...
    5. Knisely MR, et al. CYP2D6 drug-gene and drug-drug-gene interactions among patients prescribed pharmacogenetically actionable opioids. Appl Nurs Res 2017; 38: 107-110. Go to original source... Go to PubMed...
    6. Cazet L, et al. Interaction between CYP2D6 inhibitor antidepressants and codeine: is this relevant? Expert Opin Drug Metab Toxicol 2018; 14: 879-886. Go to original source... Go to PubMed...
    7. Takusagawa S, et al. Intestinal absorption mechanism of mirabegron, a potent and selective β₃-adrenoceptor agonist: involvement of human efflux and/or influx transport systems. Mol Pharm 2013; 10: 1783-1794. Go to original source... Go to PubMed...
    8. Misaka S, et al. Green tea ingestion greatly reduces plasma concentrations of nadolol in healthy subjects. Clin Pharmacol Ther 2014; 95: 432-438. Go to original source... Go to PubMed...
    9. Jeon H, et al. Apple juice greatly reduces systemic exposure to atenolol. Br J Clin Pharmacol 2013; 75: 172-179. Go to original source... Go to PubMed...
    10. Lilja JJ, et al. Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of celiprolol. Clin Pharmacol Ther 2003; 73: 192-198. Go to original source... Go to PubMed...
    11. Cheema P, El-Mefty O, Jazieh AR. Intraoperative haemorrhage associated with the use of extract of Saw Palmetto herb: a case report and review of literature. J Intern Med 2001; 250: 167-169. Go to original source... Go to PubMed...
    12. Breu W, Hagenlocher M, Redl K, Tittel G, Stadler F, Wagner H. Anti-inflammatory activity of sabal fruit extracts prepared with supercritical carbon dioxide. In vitro antagonists of cyclooxygenase and 5-lipoxygenase metabolism Arzneimittelforschung 1992; 42: 547-551.
    13. Troost J, et al. Effects of strong CYP2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosin. Br J Clin Pharmacol 2011; 72: 247-256. Go to original source... Go to PubMed...
    14. Study INT4285 (http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-287_Uroxatral_BioPharmr_P2.pdf).
    15. Study SI06008 (https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022206s000_ClinPharmR.pdf).
    16. Hammond KP, et al. Priapism induced by boceprevir-CYP3A4 inhibition and α-adrenergic blockade: case report. Clin Infect Dis 2014; 58: e35-e38. Go to original source... Go to PubMed...
    17. Lundahl A, et al. The effect of St. John's wort on the pharmacokinetics, metabolism and biliary excretion of finasteride and its metabolites in healthy men. Eur J Pharm Sci 2009; 36: 433-443. Go to original source... Go to PubMed...
    18. Lochner S, Kirch W. Does St. John's wort interact with finasteride? Dtsch Med Wochenschr 2011; 136: 1746. Go to original source... Go to PubMed...
    19. Study 100512. In: Clinical Pharmacology and Biopharmaceutics Review: NDA 21-400 (Amendment), Bayer Corporation, February 19, 2003: 28-34.
    20. Study 010229. In: FDA Medical Review: Levitra®, Application Number 21-400, Appendix J, Bayer, 2002. (http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra_Medr_P5.pdf).
    21. Study H6D-EW-LVEV in Clinical Pharmacology and Biopharmaceutics Review: Cialis® (tadalafil) 2003: 53-67. (http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-368_Cialis_BioPharmr_P1.pdf).
    22. Gallati L, et al. Interaction between tadalafil and itraconazole. Ann Pharmacother 2005; 39: 200. Go to original source... Go to PubMed...
    23. Study H6D-EW-LVAZ. In: IC351 (LY450190): Common Technical Document, Section 2.7.2 - Summary of clinical pharmacology studies. Pharmaceuticals and Medical Devices Agency, Tokyo, Japan, 2009. (http://www.pmda.go.jp/drugs/2009/P200900050/530471000_22100AMX02266000_K100_2.pdf).
    24. Paul GA, et al. Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. Br J Clin Pharmacol 2005; 60: 107-112. Go to original source... Go to PubMed...
    25. Wrishko RE, et al. Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects. J Clin Pharmacol 2008; 48: 610-618. Go to original source... Go to PubMed...
    26. Jetter A, et al. Effects of grapefruit juice on the pharmacokinetics of sildenafil. Clin Pharmacol Ther 2002; 71: 21-29. Go to original source... Go to PubMed...
    27. Mutasim A, et al. The effects of pummelo juice on pharmacokinetics of sildenafil in healthy adult male Jordanian volunteers. Eur J Clin Pharmacol 2010; 66: 159-163. Go to original source... Go to PubMed...
    28. Lenssen R, et al. Analysis of drug-related problems in three departments of a German University hospital. Int J Clin Pharm 2016; 38: 119-126. Go to original source... Go to PubMed...
    29. Hebenstreit D, et al. Drug-Drug Interactions in Prostate Cancer Treatment. Clin Genitourin Cancer 2019; pii: S1558-7673(19): 30154-5. Go to original source... Go to PubMed...
    30. Michel MC, et al. Drug-drug interactions in urology. Urologe A 2009; 48: 264-269. Go to original source... Go to PubMed...
    31. Gur S, et al. Update on drug interactions with phosphodiesterase-5 inhibitors prescribed as first-line therapy for patients with erectile dysfunction or pulmonary hypertension. Curr Drug Metab 2013; 14: 265-269. Go to original source... Go to PubMed...
    32. Bensalah N, Garcia S, Rose FX, Bedouch P, Conort O, Juste M, Roubille R, Allenet B, Tod M, Charpiat B. How to act when an alpha-blocker is associated with a potent inhibitor of CYP3A4. Prog Urol 2017; 27: 275-282. Go to original source... Go to PubMed...

    Return to the content


    Pharmacy for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.